Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayside Health
• Collaborators: Baker Heart Research Institute; The Alfred
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Enzyme Inhibitors; Perindopril

Criteria

Inclusion Criteria:

• Age 18-40

• Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria

Exclusion Criteria:

• Age <18, >40

• Women of child-bearing potential not on adequate contraception

• Serum creatinine of >0.11

• A history of intolerance to ACEI

• Patients on angiotensin receptor blockers

• Blood pressure >140/90mmHg

• History of previous aortic surgery